We acknowledge a theoretical risk that lenalidomide’s immune-stimulatory effects—through T-cell activation, restoration of immune-synapse function, and cytokine induction (e.g., IL-21)—could enhance Tfh-cell activity or modify the tumor microenvironment (65, 66). The gene discussed is IL21; the disease is neoplasm.